PLANTATION, Fla., June 27 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today reported that United Kingdom brokerage firm, Williams de
Broe Plc, a subsidiary of ING, updated its research coverage on Viragen and
reiterated its "Buy" recommendation for their risk-oriented institutional
clients seeking aggressive growth.
In a research update distributed to investment professionals, Senior
Research Analyst, Dr. Peter Cartwright, states, "The Avian project has made
excellent progress over the past 12 months and is fast reaching the point
where it will be a material factor in the share price. We expect additional
milestones and partnering opportunities to drive the near-term valuation."
Dr. Cartwright's report is not intended for private customers or U.S.
investors.
Dr. Cartwright also comments on the most recent approval for
Multiferon(R), "Viragen has also issued a press release relating to its main
activity, the supply of Multiferon, a natural human alpha interferon, for use
in infection, oncology and hepatitis settings where commercially established
recombinant interferons are not fully effective. The announcement detailed a
regulatory approval in Chile. Pentafarma S.A., a subsidiary of Fresenius
Medical Care, will distribute the product."
Viragen does not maintain an investment banking relationship with Williams
de Broe or with its parent company, ING, or related subsidiaries and no fee or
compensation was exchanged for this research report. An investment in
Viragen, or its majority-owned subsidiary, Viragen International, Inc.
(OTC Bulletin Board: VGNI), is highly speculative and additional risk factors
are detailed in SEC filings, which are available upon request or at Viragen's
website.
About Williams de Broe:
A Member of the London Stock Exchange and one of the longest established
stockbroking firms in the City of London, Williams de Broe has maintained its
reputation for independent advice, quality of research and high standards of
service for over 130 years.
For more information, please visit: http://www.wdebroe.com .
About Viragen, Inc.:
Viragen researches, develops and commercializes pharmaceutical products
designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include: Multiferon(R), a natural human alpha interferon,
approved for sale in various international markets; and humanized anti-cancer
monoclonal antibodies. Viragen is also pioneering the development of Avian
Transgenic Technology, with the renowned Roslin Institute, as a
biomanufacturing platform for the large-scale, efficient and economical
production of therapeutic proteins.
For more information, please visit: http://www.Viragen.com .
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
http://www.wdebroe.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
